Masahiro Fukuda
5PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Apr 23, 2024
Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus: A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study).Masahiro Fukuda, Ichiro Sakuma, Yutaka Wakasa
|Jul 07, 2022
Poor glycemic control rather than types of diabetes is a risk factor for sarcopenia in diabetes mellitus: The MUSCLES-DM study.Yoshihisa Hiromine, Shinsuke Noso, Hiromi Rakugi
|May 11, 2019
Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: The Multicenter Study for Clarifying Evidence for Sarcopenia in Patients with Diabetes Mellitus.Ken Sugimoto, Yasuharu Tabara, Hiroshi Ikegami
|Aug 24, 2018
Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia.Masahiro Fukuda, Kunihiro Doi, Masahiro Sugawara
|Apr 17, 2018
Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study.Takashi Sasaki, Masahiro Sugawara, Masahiro Fukuda
Pageof 1
